Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 81 Neoplasm Metastasis 10 Prostatic Neoplasms, Castration-Resistant 5 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 4 Metastatic Castration-Resistant Prostate Cancer 3 Urogenital Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Primary Myelofibrosis 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Myeloproliferative Disorders 2 Myelodysplastic Syndromes 2 Multiple Myeloma 2 Metastatic Castration-resistant Prostate Cancer (mCRPC) 2 Metastatic Castration-resistant Prostate Cancer 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Colorectal Neoplasms 2 Castration-resistant Prostate Cancer 2 Bulbo-Spinal Atrophy, X-Linked 2 Breast Neoplasms 2 Bites and Stings 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Solid Tumours 1 Salivary Gland Neoplasms 1 Prostatic Diseases 1

Interventions

enzalutamide 1 darolutamide 1 apalutamide 1 abiraterone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Prostate Carcinoma × abiraterone × Clear all

NCT05612880 2025-01-09

Physical Function During ARSI Treatment

UNC Lineberger Comprehensive Cancer Center

Advanced Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡